A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

362

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle-invasive Urothelial Carcinoma

Interventions

DRUG: Autogene Cevumeran
DRUG: Nivolumab
DRUG: Saline

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]